GlassScriptPhysician profile
Elie Klam
NPI 1336343672
$6,245.51
in general payments reported to CMS, 2019-2025
30 companies · $1,145 in 2025
The $1,145 reported for 2025 was more than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
See the full distribution for Endocrinology, Diabetes & Metabolism
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,035 · 2020: $786 · 2021: $583 · 2022: $323 · 2023: $726 · 2024: $647 · 2025: $1,145.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,503 · Education: $15.60.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,502.89 |
| Education | $15.60 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,459.39 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $509.22 | 2019-2021 | |
| Amgen INC. | $419.43 | 2019-2024 | Evenity, Prolia |
| Corcept Therapeutics | $367.23 | 2019-2025 | Korlym |
| Lilly USA, LLC | $360.58 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Abbott Laboratories | $261.73 | 2019-2025 | Freestyle Libre 3, Freestyle Libre 2 |
| Xeris Pharmaceuticals, INC. | $261.28 | 2021-2025 | Recorlev, Gvoke Hypopen |
| Insulet Corporation | $249.69 | 2019-2025 | Omnipod |
| Mannkind Corporation | $241.42 | 2019-2025 | |
| Sanofi-Aventis U.S. LLC | $228.95 | 2019-2024 | |
| Tandem Diabetes Care, INC. | $206.55 | 2020-2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Boehringer Ingelheim Pharmaceuticals, INC. | $191.66 | 2019-2025 | Jardiance, Synjardy |
| Medtronic, INC. | $187.99 | 2023-2025 | Minimed 780g |
| Medtronic Minimed, INC. | $178.92 | 2019-2020 | |
| Ascendis Pharma Endocrinology INC | $138.94 | 2023 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neurocrine Biosciences, INC. | $136.93 | 2025 | |
| Antares Pharma, INC. | $135.41 | 2019-2020 | |
| Kyowa Kirin, INC. | $133.24 | 2025 | |
| Abbvie INC. | $100.52 | 2019-2020 | |
| Beta Bionics, INC. | $80.72 | 2024-2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Inset, Ilet Insulin Infusion Kit Contact Detach |
| Dexcom, INC. | $79.37 | 2019-2025 | Dexcom G6 Transmitter |
| Lifescan, INC. | $73.27 | 2019-2020 | |
| Sequel Med Tech, LLC | $64.79 | 2025 | Twiist |
| Merck Sharp & Dohme LLC | $39.02 | 2019 | |
| Janssen Pharmaceuticals, INC | $33.34 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $31.39 | 2020 | |
| Shire North American Group INC | $29.64 | 2019 | |
| Verity Pharmaceuticals INC. | $16.76 | 2024 | Tlando |
| Pfizer INC. | $14.29 | 2023 | |
| Amarin Pharma, INC. | $13.84 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Elie Klam listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.